News

TOKYO, May 22, 2018  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced restructuring of operations in Japan and introduction of the early retirement incentive program. To realize “Strategic Plan 2018” which was announced today, Astellas focus on building and optimizing its organizational capabilities and continue pursuing Operational Excelle...

Tokyo,May 22,2018 -MSD K.K. (head office: Chiyoda-ku, Tokyo; President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (head office: Chuo-ku, Tokyo; President and CEO; Kenji Yasukawa; “Astellas”) today announced the release of SUJANU® Combination Tablets co-developed by the two companies for the treatment of type-2 diabetes, combining the DPP-4 inhibitor sitagliptin phosphate hydrate (trade na...

TOKYO – May 16, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that a wide selection of abstracts highlighting the Company’s diverse oncology portfolio across a broad range of cancers have been accepted for oral and poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5 in Chicago. Highlig...